Abstract. Breast cancer is a public health problem in the Western countries. Several studies have shown that BRCA2, like BRCA1 oncosuppressors, are strongly involved in hereditary and sporadic mammary carcinogenesis. It has also been suggested that soy has a protective effect against breast cancer in Asia and, more particularly, phytoestrogens such as daidzein and genistein. Thus, phytoestrogens may have an impact on the expression of BRCA2 gene, and there is a possible link between BRCA2 and genes acting around the BRCA2. To focus on these processes, we set up the BRCA2 specific knockdown by RNA interference in two breast tumor cell lines (MCF-7 and MDA-MB-231) and also in a non-tumorigenic breast cell line (MCF-10a). After inhibition of BRCA2 expression, cells were maintained in different conditions and treated with either daidzein or genistein or left untreated. Microarray analysis of mRNAs isolated from the BRCA2 knocked down MCF-7, MDA-MB-231, and MCF10a cell lines after being treated with phytoestrogens showed 35 differentially expressed genes between positive-ERß cells and negative-ERß cells. After genistein or daidzein treatments, BRCA1 was found to be up-regulated when knocked down with BRCA2-siRNA MCF-7 and BRCA2 was found to be up-regulated when knocked down with BRCA2-siRNA MDA-MB 231 cells. In MCF-10a, we observed a significant decrease in BAX and BCL2 expressions with a greater effect of daidzein. We also found an increase in BRIP expression between genistein and daidzein treatment knocked down with BRCA2-siRNA MCF-7 and MDA-MB-231 cell lines.
Introduction
Despite many advances in early detection, prevention and treatment, the incidence of breast cancer is increasing and remains a leading cause of mortality among women. It has been shown that many factors are involved in carcinogenesis. Genetic, hormonal and environmental factors are all important in breast cancer risk. The genetic factor is the mutation in BRCA1 or BRCA2 oncosuppressors (usually hereditary) and hazardous mutations that can lead to a decrease in the BRCA1 and/or BRCA2 expression (1, 2) . Hormonal change in the female endocrine system occuring at different stages of life is also an important factor. Finally, environmental factors, which widely vary by geographical region, effect the onset of breast cancer. Indeed, it has been found that the incidence of breast cancer is higher in the West when compared to Asia (3) . Following a study on migrant people, the influence of diet on the development of breast cancer in women was revealed. Hence, many studies have emphasized the role of soy consumption in preventing breast cancer, and especially phytoestrogens contained in the food (4) . Genistein and daidzein are the main soybean phytoestrogens that have the specificity of having a chemical structure very close to the human estrogen and, therefore to the estrogenic activity (5, 6) . Thus, we investigated the effects of genistein and daidzein on the expression of the BRCA2 oncosuppressor following its reduction or elimination by specific RNA interference in human breast cells lines (MCF-7, MDA-MB-231 and MCF-10a). Small inhibitory RNA (SiRNA) technology results in degradation of the mRNA for the target gene, and can be used to specifically reduce gene expression, in this case BRCA2. Knocked down BRCA2 breast cell lines were then tested by pangenomic microarrays ONCOLOGY REPORTS 23: 647-653, 2010 647 Phytoestrogens regulate the expression of genes involved in different biological processes in BRCA2 knocked down  MCF-7, MDA-MB-231 and MCF-10a cell lines for their response to concomitent treatment with phytoestrogens and capacity to modify gene targeting and effects on whole genone transcriptomic expression.
Materials and methods
Cell cultures. MCF-7 cells (ATCC), originating from invasive breast carcinoma, were cultured in RPMI-1640 (Invitrogen SARL, 95613 Cergy Pontoise, France) containing 15% heatinactivated fetal bovine serum (FBS), 2 mM L-glutamine, 20 μg/ml gentamycin and 0.04 U/ml insulin at 37˚C. They were kept in a humidified atmosphere of 5% CO 2 . This cell line has a positive estrogen-receptor status (ER· + /ß + ). MDA-MB-231 cells (ATCC) were grown in L-15 Leibovitz (Invitrogen SARL) supplemented with 2 mM L-glutamine, gentamycin (20 μg/ml) and 15% heat-inactivated FBS at 37˚C and without CO 2 atmosphere. This cell line has an ER· -/ß + status. The MCF-10a cell line (ATCC) was established from fibrocystic breast disease. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 (Invitrogen SARL) with 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml insulin and 500 ng/ml hydrocortisone and 15% heat-inactivated horse serum. Cells were grown in a 37˚C humidified atmosphere with 5% CO 2 . This cell line has a negative estrogen receptor status for each receptor isoform (ER· -/ß -).
Knock down of BRCA2 using siRNA and transfection and phytoestrogen treatment. BRCA2-specific siRNA were purchased from Santa Cruz Biotechnology (sc-29825). The siRNA sequences were 5'-CCA AGG AUG UUC UGU CAA Att-3', 5'-CAA GCU ACA UAU UGC AGA Att-3', and 5'-GAA ACG GAC UUG CUA UUU Att-3'. MCF-7, MCF-10a, and MDAMB-231 cells were grown for 24 h in 6-well plates. At 50% of confluence, cells were transfected with siRNA (final concentration 50 nM) diluted in the siRNA transfection reagent (sc-29528, Santa Cruz Biotechnology) according to the manufacturer's protocol. The negative control was made from a cell culture grown under the same conditions, but without siRNA. For transfected cells, after a 24-h incubation period, they were cultivated in their respective medium without antibiotics. The phytoestrogen treated-cells were incubated for 48 h after transfection, in the presence of 18.5 μM genistein or 78.5 μM daidzein. These phytoestrogen concentrations correspond to the IC50 (7), they were previously assessed by flow cytometry. Finally, RNA extractions were carried out after a 72-h incubation period corresponding to the beginning of the transfection with the siRNA and followed by the phytoestrogen treatment of the cell lines.
RNA extraction. After 72 h of treatment, the total RNA isolated from cells transfected or non-transfected previously in a 6-well plate was extracted using 1 ml RNA-PLUS (MP Biomedicals) in each well according to the manufacturer's protocol. Six wells were pooled for each condition. The RNA quality was checked by electrophoresis using a Bioanalyzer 2100 with RNA 8000 Nanodrop LabChip ® and BioSizing A.02.11 software (Agilent Technologies). The samples were then stored in liquid nitrogen.
Reverse transcription and quantitative PCR of BRCA2 mRNA expression. RNAs were diluted to 1.6 g/μl in water DEPC. The reverse transcription was performed using the First-Strand cDNA Synthesis Kit (Amersham Biosciences), according to the manufacturer's instructions. In each cell line, we assayed by quantitative PCR, the expression of BRCA2 mRNA in transfected siRNA-specific BRCA2 cells and in transfected cells treated with genistein and daidzein by comparison to controls of non-transfected cells. cDNA (5 ng/μl) was diluted in water treated for PCR. We added 5 μl of this solution to 20 μl Mix reaction, composed of 62.5 nM probe, 50 nM forward and reverse primers for 18S RNA, 250 nM probe and 500 nM primers specific for BRCA2, and 12.5 μl PCR Mix (Universal PCR Master Mix Taqman, Roche) that consisted of dNTP, the DNA polymerase and buffer reaction 2X. PCR reaction was performed for 40 cycles divided into 15-sec denaturations at 95˚C and 1-min hybridizationelongation at 60˚C. Two independent total RNA extractions were done as two independent reverse transcriptions with a RNA extraction. The data were generated in triplicate and expressed as mean ± SD. The results were analyzed with significant p-value differences between control and assays.
Oligo microarray, RNA labeling and hybridization. Whole Human Genome Microarray Kit, 4 x 44 K (G4112F) were provided by Agilent Technologies. We amplified and labeled 200 ng of total RNA using Low RNA Input Fluorescent Linear Amplification Kit PLUS, two-color (5188-5340, Agilent) according to the manufacturer's instructions. Amplified RNA was labeled by fluorescent probes with Cy5-CTP for the treated samples and Cy3-CTP for the control samples corresponding to control cells without any treatment or knock down and competitively hybridized to pangenomic arrays. Hybridization was carried out at 60˚C overnight. Slides were washed using a wash buffer kit (5188-5327, Agilent) and a stabilization solution (5185-5979, Agilent Technologies). The fluorescent intensities were obtained with a DNA microarray scanner (G2565CA, Agilent Technologies) and signal quantitative values were calculated using the internal feature extraction software (Agilent Technologies). For each treatment, 3 microarrays were done and analyzed for MDA-MB-231 and MCF-10a and 4 microarrays for MCF-7.
Microarray analysis. Signal intensity ratios (Cy3/Cy5) of each gene were converted into a logarithmic value (log2) with LimmaGUI 1.7.0 using R 2.2.0 (8). Then, Edward's background correction was performed. This adjustment substracts local and off-spot signal from each spot's foreground with a log-linear interpolation of lower-intensity spots designed to produce positive net values. Normalizations were performed within and between-array via a global lowess method (9) . This was based on local estimation of intensities and a regression calculation weighted toward similar spots. Negative controls were removed from the data set. Using a differential expression cut-off of 2-fold and hierarchical clusters obtained with TIGR MeV version 4.2.02 software using a clustering method, a complete-linkage Pearson correlation was performed. Clusters were colored in red for up-regulation and in green for down-regulation in comparison to control.
Rate calculation. In order to find if there is a difference between ER-positive · or ß and ER-negative · or ß cell lines, we first performed a hierachical clustering and a t-test was used to find significantly different expression of genes between the treatments. We used the Pearson correlation and a cut-off of 2-fold. A p-value was calculated to show if there was a significant difference between each condition. Therefore, significantly expressed genes were classified according to implicated biological pathways by using EASE version 2.0 software (10) and Gene Ontology (GO) database.
Results

Knock down of BRCA2 transcript levels in cell lines by Q-PCR.
Quantification was carried out for MCF-7, MCF-10a and MDA-MB-231 human breast cell lines in order to measure the specific BRCA2-siRNA inhibition on BRCA2 expression. Relative gene expression was determined using the comparative CT (threshold cycle) method consisting of normalizing the number of target gene copies to the endogenous reference gene (18S rRNA), designated as the calibrator. The amount of mRNA in transfected cell lines, whether treated or not with phytoestrogens was then normalized to control cells without any intervention. In Fig. 1 , results are presented with the mean ± standard deviation with three replications. MCF-7, MCF-10a and MDA-MB-231 cells, after transfection by specific BRCA2-siRNA, revealed 84, 96 and 74% inhibition in BRCA2 expression, respectively as compared to control cells. These results were statistically significant with p<0.01 according to the Student's t-test (11) .
Discrimination according to the ER cell status.
With pangenomic microarrays, using TIGR MeV version 4.2.02 software (The Institute for Genomic Research), hierarchical clustering was performed and followed with a t-test analysis.
We carried out 2 discriminations according to estrogen receptor isoform · (Fig. 2A) or ß (Fig. 2B) . For each discrimination, we defined 2 groups. The first group was cells exhibiting ER· (MCF-7) or not exhibiting it (MDA-MB-231; MCF-10a). The second group was cells exhibiting ERß (MCF-7; MDA-MB-231) or not exhibiting it (MCF-10a). Results showed 888 differentially expressed genes between positive-ER· cells and negative-ER· cells (data not shown) and 35 differentially expressed genes between positive-ERß cells and negative-ERß cells (Fig. 2) . Moreover, we found 3 common differentially expressed genes between the 2 discriminations: ATP11A, GBP3, STK16.
Discrimination according to isoflavone treatment. We also performed discrimination according to genistein or daidzein treatment in MCF-7 (Fig. 3A) , MDA-MB-231 (Fig. 3B) and MCF-10a (Fig. 3C) (Fig. 3) .
Significant results were observed in BRCA1 and BRCA2 expression after genistein or daidzein treatment (Table I) and respectively in MCF-7 and MDA-MB-231 (Fig. 4) . In MCF-7, we noted a 2-fold change ± 0.07 of BRCA1 expression after genistein treatment and a 2.6-fold change ± 0.18 after daidzein treatment (Fig. 4) . Nevertheless, BRCA2 expression was not influenced in MCF-7 after phytoestrogen supplementation (Table I) . In MDA-MB-231, BRCA1 expression was not Table I . Gene average of BRCA1 and BRCA2 after genistein or daidzein treatment in MCF-7, MDA-MB-231 and MCF-10a knocked down with BRCA2-siRNA. -10a) . In bold type, common genes (3) expressed according to both ER· and ERß discriminations. Significant expressed genes were discriminated using a t-test and we confirmed our results by calculating adjusted p-value using the SAM method (Significant Analysis of Microarray) to attest significant effect between genistein and daidzein treatment. Gene ontology (GO) was used to identify implicated biological process. (Table I ), but BRCA2 expression was increased by 3±1.06 after genistein supplementation and increased by 9.4±1.4 with daidzein (Fig. 4) . There was no significant effect on BRCA1 and BRCA2 expression after genistein or daidzein treatment in the fibrocystic breast cell line MCF-10a (Table I) but we observed a significant decrease in BAX and BCL2 expression (Fig. 5A) . Moreover, we noted a higher effect of daidzein than genistein on BAX and BCL2 expression (Fig. 5B) . We also found a differential BRIP expression between genistein and daidzein treatment, more importantly with daidzein ( Fig. 6 ) in MCF-7 and MDA-MB-231 cell lines.
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Discussion
Our objective was to understand the effects of the transcient ablation of BRCA2 gene expression in human breast cell lines (MCF-7, MDA-MB-231 and MCF10a) combined with phytoestrogen treatment (18.5 μM genistein or 78.5 μM daidzein), also, to investigate the consequence on the whole genome by pangenomic microarrays. Other researches have previously performed studies on the molecular consequences of transient or stable BRCA2 deficiency in human breast cell lines (12) and in mice using siRNA (13) .
Tripathi and Chaudhuri (12) reported observations on the effect of transient depletion of BRCA2 gene expression on human mammary epithelial cells (HMEC) and BT549 human breast carcinoma cells. They performed microarray analysis of the mRNAs isolated from these BRCA2 knocked down cells as well and showed a limited number of 14 significant genes that are down-regulated as an immediate consequence.
To study this, we used RNA interference in human breast cells (MCF-7, MCF-10a, and MDA-MB-231) to down- Discrimination according to phytoestrogen treatment: 14 common differentially expressed genes between MCF-7, MDA-MB-231 and MCF-10a cells knocked down with BRCA2-siRNA. Significant expressed genes were discriminated using a t-test and an adjusted p-value was calculated using the SAM method to attest significant effect between genistein and daidzein treatment. Gene ontology (GO) was used to identify implicated biological process.
- regulate BRCA2. Genistein and daidzein 72-h treatments were added to this transitory loss of function, and we performed a global gene expression profiling by DNA microarray analysis. The isoflavones were added to observe their effect on the BRCA2 ablation. The breast cell lines used here exhibit different ER status, so we compared gene expression changes to ER status as well as to genistein or daidzein treatment. After a treatment discrimination, the MCF-7 (ER· + /ß + ) cell line showed a significant up-regulation of the oncosuppressor BRCA1 transcript after BRCA2 specific knock down and additional treatment by either genistein or daidzein isoflavones. These results were in comparison to the control group. Under the same analysis conditions, we found also a significant up-regulation of BRCA2 mRNA in MDA-MB-231 (ER· -/ß + ) cell line, and modulations of the apoptosis-related genes BAX and BCL2 in MCF-10a (ER· -/ß -) cell line. Moreover, discrimination according to phytoestrogen treatment revealed 14 common differentially expressed genes between the three cell lines, including the BRIP1 and P53 genes.
Chromosome aberrations in BRCA2-deficient cells have been attributed to loss of normal control by BRCA2 of the eukaryotic strand exchange protein RAD51 required during the S phase for DNA repair and homologous recombination (14, 15) . Abnormal cytokinesis has been also suggested to explain chromosomal instability and aneuploidy in cells deficient of BRCA2 (16) . Our results suggest a potential role of phytoestrogens to limit genome instability in BRCA2 deficient cells by promoting BRCA1 and BRCA2 expressions.
On the basis of its interaction with BRCA1, the tumor suppressor BRIP1 is also considered a potential breast cancer susceptibility gene. The DEAH helicase family member BRIP1 was first identifed as a 130-kDa protein directly interacting with the C-terminal (BRCT) domains of BRCA1; hence, the name BRIP1 (BRCA1-interacting protein). The BRIP1/BRCA1 interaction was found to contribute to the DNA repair activity of BRCA1 (17) . In our study, BRIP1 was found significantly overexpressed after genistein and daidzein treatments under BRCA2 knock down conditions in comparison to the control group. Recently, it has been reported that BRCA1/BRCA2-associated BRIP1 activation was required for progression through the S phase, and it has been shown that depletion of BRIP1 as well as BRCA1 by RNA interference, resulted in delayed G 1 /S progression (18) . Our results showed an up-regulation of BRIP1 after phytoestrogen treatments under BRCA2 knock down conditions, and also suggested a plausible link between BRCA2, BRIP1 and phytoestrogen pathways. Further investigation will certainly help to gain insights into the role of BRIP1 in the BRCA-breast cancer pathways and its tumor suppression function.
In our study, we obtained a down-regulation of BCL2 and BAX gene expressions after phytoestrogens treatments under BRCA2 knockdown conditions. In a recent study, Castro et al reconstructed the evolutionary scenario that linked apoptosis with genome stability pathways in a functional human gene/protein association network (19) . They demonstrated how genome stability and apoptosis were co-opted during evolution recruiting genes that merge both systems. They found the apoptosis-related BAX and BCL2 genes as important to cancer as the BRCA1, BRCA2, and P53 genes. Our results corroborate their analysis and suggest a link between apoptosis, BRCA-breast cancer and phytoestrogen pathways.
In conclusion, our results showed a limited number of genes that are modulated as an immediate consequence of the decrease of BRCA2 and phytoestrogen treatments. A number of important breast cancer genes (BRCA1, BRCA2) and apoptosis-related genes (BAX, BCL2) have also been modulated by this transitory oncosuppressor knock down and sensitivity revealed to the phytoestrogen supplementations. Taken together, these results suggested a potential chemopreventive effect of phytoestrogens in promoting apoptosis and maintenance of genome stability.
